chevron_leftBack
As of 24 April 2025, Modalis Therapeutics Corp. has a market cap of $40.26M USD, ranking #26020 globally and #2915 in Japan. It ranks #2627 in the Healthcare sector, and #570 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$40.26MUSD
5.74B JPY
Enterprise Value
$15.11MUSD
2.16B JPY
EBITDA (TTM)
-$9.34MUSD
-1.34B JPY
Net Income (TTM)
-$9.24MUSD
-1.32B JPY
Company Profile
Country (HQ)
Sector
Healthcare
CEO
Haruhiko Morita
open_in_new
Employees
14
Founded
2016
Website
modalistx.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 1.3% | 1.3% | -13% | -23% | -15% | 2.6% |
Upcoming Earnings
Earnings Date
Wed, May 7
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
4883
株式会社モダリス Ordinary Shares
ISIN: JP3922600006
Shares Out.:
Shares Outstanding:
74.434M1
Shares Float:
67.311M2
|
78 JPY |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Modalis Therapeutics Corp.
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. It is developing therapies for genetic diseases using its proprietary CRISPR-GNDM technology that enables to control gene expressions through modulating the switch (epigenetics of a specific locus. The company has a. joint research agreement with JCR Pharmaceuticals Co., Ltd. to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was founded in 2016 and is headquartered in Tokyo, Japan.
